Treatment of metastatic colorectal cancer also involves blocking proteins that prevent the immune system from attacking cancer cells (immune checkpoint inhibitors) and HER2-specific or CAR T cells (Chimeric Antigen Receptor T cells) reactive to the tumor [10]. This evidence concerns the gene ERBB2 and cancer.